• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Ciprofloxacin
    4 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Ciloxan
    Novartis
    RX
    partial basket chart
    Ciloxan

    Quinolone. Ciprofloxacin (as HCl) 3 mg/ml.
    EYE AND EAR DROPS (SOL.): 5 ml.
    Adults and child from 1 yr:
    Corneal ulc.: 2 drops every 15 mins. for
    first 6 hrs., then 2 drops every 30 mins.
    for rest of day. 2nd day: 2 drops hrly.
    On 3rd-14th day: 2 drops every 4 hrs.
    for up to 14 days.
    Bact. conjunct: 1-2 drops into conjuct.
    sac(s) every 2 hrs. for 2 days, then 1-2
    drops every 4 hrs. for next 5 days.
    Otic use: 3 to 4 drops, 2-4 /d, or more
    frequently, if required.
    In gen., the duration of tmt does not
    exceed 5-10 ds.
    For either ind. a max. duration of ther.
    of 21 days is recommend.
    Corneal ulc., conjunct. caused by suscep.
    gram pos., gram neg. microorg. for adults
    and ped. pts > 1 yr.
    For local./diff. otitis externa accomp. by a
    strong inflamm. react. and of which the
    strains are suscept., and for the acute flare-up of a chronic otitis media. In this
    case, a mucopurulent secret.
    In other infect. of the ear in which
    Pseudom. aerug. and/or other suscept.
    strains may be suspect., it can be used
    under the strict superv. of an ear specialist.
    It must be understood that this is not a
    routine tmt and improper use must be
    avoided.
    C/I: Hypersens. to the product or other
    quinolones.

    Cipro-Teva 2 mg/ml
    Abic
    RX
    not in the basket chart
    Cipro-Teva 2 mg/ml

    Fluoroquinolones, Quinolone. Ciprofloxacin (as lactate) 2 mg/ml.
    BOTTLE: 10, 24 × 100 ml, 200 ml. Dosage ajust. accord. to the type of infec.
    Adults: Broad spectrum antibiotic for infec. caused by ciprofloxacin sensit. pathogens.
    Child. & adolesc.: Broncho-pulmon., infec. in cystic fibrosis (CF) caused by Pseudomonas a.
    Complic. UTS’s and pyelonephritis.
    Inhalation anthrax (post-exposure prophylax. & curative tmt.).
    Ciprofloxacin may also be used to treat severe infec. in child. & adolesc. when there is no other alternative.
    Tmt. should be init. only by physicians who are experienced in the tmt. of CF and/or severe infec. in child. & adolesc.
    C/I: Hypersens. to the active ingredient/ other quinolones. Concom. admin. of ciprofloxacin and tizanidine.

    Ciprodex 500
    Dexcel
    RX
    partial basket chart
    Ciprodex 500

    Fluoroquinolone. Ciprofloxacin (as hydrochloride) 500 mg.
    CAPS: 10 x 500mg. Upper & lower respirat. tract infec.: 500-750mg ×2/d for 7-14 d.
    Malig. extern. otitis: 750 mg ×2/d for 28 d.  up to 3 mnths.
    Uncomplic. cystitis: 250-500mg ×2/d for 3 d. (in pre-menopaus. women, 500 mg single dose may be used).
    Complic. cystitis, Uncomplic. pyelonephritis: 500 mg ×2/d for 7 d.
    Complic. pyelonephritis: 500-750 mg ×2/d for at least 10 d.
    Prostatitis: 500-750 mg ×2/d for at least 14 d.
    Gonococcal urethritis & cervicitis: 500mg as a single dose.
    Epididymo-orchitis & pelvic inflamm. dis.: 500-750mg ×2/d for at least 14 d.
    Diarrhoea caused by bact. pathogens includ. Shigella spp. other than Shigella dysenteriae type 1 and empirical tmt. of severe travellers' diarrhea: 500mg twice dly. for 1 d.
    Diarrhoea caused by Shigella dysenteriae type 1: 500mg ×2/d for 5 d.
    Diarrhoea caused by Vibrio cholera:
    500mg
    ×2/d for 3 d.
    Typhoid fever: 500mg ×2/d for 7 d.
    Intra-abdom. infec. due to Gram-neg. bact.: 500-750mg ×2/d for 5-14 d.
    Infec. of the skin & soft tissue: 500-750mg ×2/d for 7-14 d.
    Bone & joint infec.: 500-750mg ×2/d for max. of 3 mnths.
    Neutropenic pts. with fever suspected to be due to a bact. infec.
    Ciprofloxacin should be co-admin. with appropriate antibact. agent(s) in accord. to official guidance: 500-750mg ×2/d over the entire period of neutrop.
    Prophylaxis of invas. infec. due to Neisseria meningitidis: 500 mg as a single dose.
    Inhalat. anthrax post-exposure prophylax., curative tmt. for persons able to receive tmt. by oral route when clinic. appropriate. Drug admin. should begin as soon as possible after susp. or confir. exposure: 500mg ×2/d for 60 d. from the confirm.of Bacillus anthracis exposure.
    See lit.
    Ped.population: CF:  20 mg/kg bdy. wt. ×2/d with a max. of 750 mg  per dose for 10-14 days.
    Complic. UTI's & pyelonephritis: 10 mg/kg bdy. wt. ×2/d to 20 mg/kg bdy. wt. ×2/d with a max. of 750 mg/dose for 10-21 d. Inhal. anthrax post-exposure prophylax. & curative tmt. for persons able to receive tmt. by oral route when clinic. appropriate. Drug admin. should begin as soon as possible after susp. or confirm. exposure: 10 mg/kg bdy. wt.×2/d to 15 mg/kg bdy. wt.×2/d with a max. of 500 mg per dose for 60 d. from the confirm. of Bacillus anthracis exposure.
    Other severe infec.: 20 mg/kg bdy. wt. ×2/d with a max. of 750 mg/dose (durat. of tmt. accord. to the type of infec.). See lit.
    Adult.: Broad spect. antibiot. for infec. caused by ciprofloxacin sensit. pathogens.
    Child.& adolesc.: Broncho -pulmon. infec. in CF caused by Pseudomonas aeruginosa.
    Complic. UTI's &pyelonephritis.
    Inhal. anthrax (post-exposure prophylax. & curative tmt.).
    Ciprofloxacin may also be used to treat severe infec. in child. & adolesc. when there is no other alternative.
    Tmt. should be initiated only by physicians who are experienc. in the tmt.  of CF and/or severe infec. in child. & adolesc. See lit.
    C/I: Hypersens. to the active subst., to other quinolones. Concom. admin. with tizanidine. See lit.

    Ciprofloxacin Teva
    Teva
    RX
    partial basket chart
    Ciprofloxacin Teva

    Quinolone. Ciprofloxacin (HCl) 250, 500, 750 mg.
    TABS: 10. Upper and lower respir. tract
    infects: 250-750 mg 2 x dly. Upper and
    lower urin. tract infects: 250-500 mg 2
    x dly. Pneumococ. pneumon. and cystic
    fibros. pts. with P. infects. of lower
    respir. tract: 750 mg 2 x dly. Other
    infects: 500-750 mg 2 x dly. For ped.
    cystic fibros. pts. aged 5-17 yrs. with
    acute pulm. exacerbat. assoc. with P.
    aeruginosa infects: 20 mg/kg 2 x dly.
    Max. dly dose: 1,500 mg.
    Infects. caused by ciprofloxacin-sens.
    pathogens: tmt. invas. infect. extern. ear;
    tmt. acute pulm. exacerbat. of cystic
    fibrosis assoc. with Pseudomonas
    aeruginosa in ped. pts. aged 5-17 yrs.
    C/I: Known hypersens. to ciprofloxacin or
    other quinolone deriv., child. and grow.
    adolesc., pregn., lact.

    CLOSE